Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.
Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E, Lomen-Hoerth C, Armon C, Tandan R, Rudnicki SA, Rezania K, Sufit R, Pestronk A, Novella SP, Heiman-Patterson T, Kasarskis EJ, Pioro EP, Montes J, Arbing R, Vecchio D, Barsdorf A, Mitsumoto H, Levin B; QALS Study Group.
Kaufmann P, et al. Among authors: armon c.
Ann Neurol. 2009 Aug;66(2):235-44. doi: 10.1002/ana.21743.
Ann Neurol. 2009.
PMID: 19743457
Free PMC article.
Clinical Trial.